Indications of PET imaging;Indicaciones de la tomografía por emisión de positrones

Medicina Clinica

Volumn 120, Issue 19, 2003, Pages 742-749

  Lomeña Caballero, Francisco Juan ^a   Perdigó, Marc Simó ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CETIR Unitat PET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; ACETIC ACID C 11; BENZODIAZEPINE DERIVATIVE; CARBON 13; COPPER 62; DEXETIMIDE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; ESTRADIOL; FLOXURIDINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE DERIVATIVE; GUANINE DERIVATIVE; IODINE 124; METHIONINE C 11; METIROSINE; MUSCARINIC AGENT; NICOTINE DERIVATIVE; NITROGEN 13; OXYGEN 15; PALMITIC ACID C 11; SEROTONIN AGONIST; TRACER; URACIL ARABINOSIDE; URACIL DERIVATIVE;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EVIDENCE BASED MEDICINE; EXPERIMENTAL ANIMAL; GLYCOLYSIS; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; INFLAMMATORY DISEASE; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

EID: 0037490209     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13048061     Document Type: Review

References (63)

1. Phelps ME. PET: the emerging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661-81.
2. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, Onko-PET III, 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-23.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
4. Reiman E, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N Engl J Med 1996;334:752-8.
5. Ruiz JA, Melgarejo M, Ossola G, Martin R, Ordovas A, Kostvintseva O. Tomógrafos PET. Rev Esp Med Nucl 2001;20:561-74.
6. Peñuelas I. Radiofármacos PET. Rev Esp Med Nucl 2001;20:477-98.
7. Chatziioannou AF, Cherry SR, Shao Y, Silverman RW, Meadors K, Farquhar TH, et al. Performance evaluation of microPET: a high-resolution lutetium oxyorthoslicate PET scanner for animal imaging. J Nucl Med 1999;40:1164-75.
8. Wahl RL. Clinical oncology update: the emerging role of positron emission tomography: Part I. Prin Pract Oncology 1997;11(1):1-18.
9. Wahl RL. Clinical Oncology Update: The emerging role of positron emission tomography: Part II. Prin Pract Oncology 1997; 1,(2):1-24.
10. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry 2001;49:211-20.
11. Rapoport SI. In vivo fatty acid incorporation into brain phospholipids in relation to signal transduction and membrane remodeling. Neurochem Res 1999;24:1403-15.
12. Barrio JR, Huang SC, Cole G, Satyamurthy N, Petric A, Phelps ME, et al. PET imaging of tangles and plaques in Alzheimer disease with highly hydrophobic probe. J Labelled Cpd Radiopharm 1999;42(Suppl):5194-5.
13. Verhoeff NP. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology 1999;147:217-49.
14. Burns HD, Hamill TG, Eng W, Francis B, Fioravanti Ch, Gibson RE. Positron emission tomography neuroreceptor imaging as tool in drug discovery research and development. Curr Op Chemical Biol 1999;3:388-94.
15. Fowler JS, Volkow ND, Wang GJ, Ding YS, Dewey SL. PET and drug research and development. J Nucl Med 1999;40:1154-63.
16. Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimaki T, Nuutila P, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001;38:561-8.
17. Tjuvajev JG, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J, et al. Non invasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996;56:4087-95.
18. Coleman RE, Tesar R, Phelps M. HCFA and expanded coverage of PET. J Nucl Med 2001;42:11N-2N.
19. Carreras JL. La tutela de la PET. Rev Esp Med Nucl 2002;21:329-32.
20. Clarke DD, Sokoloff L. Circulation and energy metabolism of the brain. In: Siegel GJ, editor. Basic Neurochemistry: molecular, cellular and medical aspects. New York: Raven Press, 1994; p. 663.
21. Tamaki N. Current status of viability assessment with positron tomography. J Nucl Cardiol 1994;1:40-7.
22. Schwaiger M, Hicks R. The clinical role of metabolic imaging of the heart by positron emission tomography. J Nucl Med 1991;32:565-78.
23. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
24. Maes A, Flameng W, Nuyts J, Borgers M, Shivalkar B, Ausma J, et al. Histological alterations in chronically hypoperfused myocardium: correlation with PET findings. Circulation 1994;90:735-45.
25. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Acurancy of currently available techniques for prediction of funcional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled date. J Am Coll Cardiol 1997;30:1451-60.
26. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with 18F-fluorodeoxiglucose positron emission tomography. Circulation 2002;105:2708-11.
27. Stumpe K, Dazzi H, Schaffner A, Von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 2000;27:822-32.
28. Kaim AH, Weber B, Kurrer M, Gottschalk J, Von Schulthess GK, Buck A. Autoradiographic quantification of 18F-FDG uptake in experimental Soft-Tissue Abscesses in Rats. Radiology 2002;223:446-51.
29. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Sem Nucl Med 2002;22:47-59.
30. Newberg A, Alavi A, Reivich M. Determination of regional cerebral function with FDG. Sem Nucl Med 2002;22:13-34.
31. Montz R, Jiménez A, Coullat T, López Ibor JJ, Carreras JL. PET en neurología y psiquiatría I. PET con FDG en el estudio del SNC. Rev Esp Med Nucl 2002;21:370-86.
32. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-7.
33. De Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-18F-fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). PNAS 2001; 98:10966-71.
34. Silverman DHS, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia. Regional brain metabolism and long-term outcome. JAMA 2001;286:2120-7.
35. Trampal C, Engler H. PET en neurología y psquiatría II. Rev Esp Med Nucl 2002;21:439-55.
36. Gámez C, Cabrera A, Sopena R, García-Belloso MJ. La tomografía por emisión de positrones (PET) en Oncología (parte I). Rev Esp Med Nucl 2002;21:41-60.
37. Cabrera A, Gámez C, Martín JC. La tomografía por emisión de positrones (PET) en Oncologia (parte II). Rev Esp Med Nucl 2002;21:131-47.
38. Cabrera A, Gámez C, García-Belloso MJ. La tomografía por emisión de positrones (PET) en Oncología (parte III). Rev Esp Med Nucl 2002; 21:304-20.
39. Kao CH, Kwan JK, Chow MJ. The role of 18F-fluorodeoxyglucose positron emission tomography in cancer screening-a preliminary report. Oncol Rep 2001;8:1145-8.
40. Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000;83:1605-11.
41. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7.
42. Delbeque D, Patton JA, Martin WH, Sandler MP. Positron imaging in oncology: present and future. En: Freeman LM, editor. Nuclear Medicine Annual. Philadelphia: Lippincott-Raven, 1998; p. 1-49.
43. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Sem Nucl Med 2002;32:35-46.
44. Tomografía por emisión de positrones(PET) con 18FDG en oncología clínica (revisión sistemática). Informe de Evaluación de Tecnologías Sanitarias no 30. Madrid: Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo, noviembre de 2001.
45. Del Sole A, Falini A, Ravasi L, Ottobrini L, De Marchis D, Bombardieri E, et al. Anatomical and biochemical investigation of primary brain tumors. Eur J Nucl Med 2001;28:1851-72.
46. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Längström B, et al. Positron emission tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-9.
47. Chung JK, Kim YK, Kim S, Lee YL, Paek S, Yeo JS, et al. Usefulness of C11-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med 2002;29:176-82.
48. Adams S, Baum RP, Struckensen T. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-60.
49. Wong RJ, Lin DT, Schöder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of 18F-fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-200.
50. Gould MK, Maclean CC, Kuschner WG, Rydzak CHE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lessions. A meta-analisis. JAMA 2001;285:914-24.
51. Richter JA, Torre W, Gámez C, Aramendia JM, Crespo A, Nicolas A, et al. Valor de la tomografía por emisión de positrones (PET)-18FDG en el cáncer de pulmón. Med Clin (Barc) 1999;113:567-71.
52. Chiti A, Schreiner F, Crippa F, Pauwels E, Bombardieri E. Nuclear medicine procedures in lung cancer. Eur J Nucl Med 1999;26:533-55.
53. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluordeoxyglucose imaging in lung cancer. Chest 2001;120:521-7.
54. Pieterman RM, Van Putten JWG, Meuzelar JJ, Mooyaart EL, Vaalburg W, Koeter GH, el al. Preoperative staging of non small cell-lung cancer with 18-fluorodeoxyglucose positron-emission tomography. N Engl J Med 2000;343:254-61.
55. Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, et al. Clinical impact of 18F fluorodeoxiglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001; 19:111-118.
56. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finko J, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889-99.
57. Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garrafa G, Bendandi M, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-4.
58. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
59. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body 18F-2-deoxyglucose positron emissiontomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-8.
60. Oyama N, Akino H, Kanamuru H, Suzuki Y, Muramoto S, Yonekura Y, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-6.
61. De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensick HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002; 42:18-23.
62. 18F] fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001;124:2223-31.
63. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28:1671-6.